FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148868762> ?p ?o ?g. }

• W2148868762 endingPage "376.e2" @default.
• W2148868762 startingPage "368" @default.
• W2148868762 abstract "ObjectiveThis study determined the average estimated total costs after treatment for peripheral arterial occlusive disease (PAOD) and evaluated the effect of postoperative complications and their consequences for the total costs.MethodsCost data on all admissions involving treatment for PAOD from January 2007 until July 2007 were collected. A prospective analysis was made using the patient-related risk factor and comorbidity (Society for Vascular Surgery/International Society of Cardiovascular Surgeons) classification, primary and secondary treatment, and prospectively registered complications. At admission, patients without complications were placed in group A, and those with complications were in group B. Prospectively registered complications were divided into patient management (I), surgical technique (II), patient's disease (III), and outside surgical department (IV). The consequences of these were divided into minor complication, no long-term consequence (1A), additional medication or transfusion (1B), surgical reoperation (2A), prolonged hospital stay (2B), irreversible physical damage (3), and death (4). The main outcome measures were total costs of patients and costs per patient (PP), with or without the presence of complications, cost of complications and costs per complication (PC), and the costs of their consequences calculated in euros (€).ResultsNinety patients (mean age, 71.4 years; 59% men) were included. Group B patients had a significantly higher American Society of Anesthesiologists (4) and Fontaine (3) classification and more secondary procedures. Total costs were €1,716,852: group A, €512,811 (PP €12,820); and group B, €1,204,042 (PP €24,081). The costs of the 115 complications were €568,500 (PC €4943). Split by the cause of the complication, costs were I, €95,924 (PC €2998); II, €163,137 (PC €8157); III, €289,578 (PC €5171); and IV, €19,861 (PC €2837). The increase of costs in group B was mainly caused by additional medication or transfusion (1B) €348,293 (61.3%), a surgical reoperation (2A) €118,054 (20.8%), or prolonged hospital stay (2B) €60,451 (10.6%). Patients who died caused 23% of the total costs.ConclusionComplications cause an increase of the average estimated total costs in the treatment for peripheral arterial occlusive disease and are responsible for 33% of these total costs. The most expensive complications were errors in surgical technique and patient's disease, resulting in surgical reoperation or additional medication, or both, or transfusion, the two most expensive consequences. This study determined the average estimated total costs after treatment for peripheral arterial occlusive disease (PAOD) and evaluated the effect of postoperative complications and their consequences for the total costs. Cost data on all admissions involving treatment for PAOD from January 2007 until July 2007 were collected. A prospective analysis was made using the patient-related risk factor and comorbidity (Society for Vascular Surgery/International Society of Cardiovascular Surgeons) classification, primary and secondary treatment, and prospectively registered complications. At admission, patients without complications were placed in group A, and those with complications were in group B. Prospectively registered complications were divided into patient management (I), surgical technique (II), patient's disease (III), and outside surgical department (IV). The consequences of these were divided into minor complication, no long-term consequence (1A), additional medication or transfusion (1B), surgical reoperation (2A), prolonged hospital stay (2B), irreversible physical damage (3), and death (4). The main outcome measures were total costs of patients and costs per patient (PP), with or without the presence of complications, cost of complications and costs per complication (PC), and the costs of their consequences calculated in euros (€). Ninety patients (mean age, 71.4 years; 59% men) were included. Group B patients had a significantly higher American Society of Anesthesiologists (4) and Fontaine (3) classification and more secondary procedures. Total costs were €1,716,852: group A, €512,811 (PP €12,820); and group B, €1,204,042 (PP €24,081). The costs of the 115 complications were €568,500 (PC €4943). Split by the cause of the complication, costs were I, €95,924 (PC €2998); II, €163,137 (PC €8157); III, €289,578 (PC €5171); and IV, €19,861 (PC €2837). The increase of costs in group B was mainly caused by additional medication or transfusion (1B) €348,293 (61.3%), a surgical reoperation (2A) €118,054 (20.8%), or prolonged hospital stay (2B) €60,451 (10.6%). Patients who died caused 23% of the total costs. Complications cause an increase of the average estimated total costs in the treatment for peripheral arterial occlusive disease and are responsible for 33% of these total costs. The most expensive complications were errors in surgical technique and patient's disease, resulting in surgical reoperation or additional medication, or both, or transfusion, the two most expensive consequences." @default.
• W2148868762 created "2016-06-24" @default.
• W2148868762 creator A5001451471 @default.
• W2148868762 creator A5013152941 @default.
• W2148868762 creator A5016288477 @default.
• W2148868762 creator A5024073608 @default.
• W2148868762 creator A5058061659 @default.
• W2148868762 creator A5058704158 @default.
• W2148868762 date "2008-08-01" @default.
• W2148868762 modified "2023-09-27" @default.
• W2148868762 title "Treatment for peripheral arterial obstructive disease: An appraisal of the economic outcome of complications" @default.
• W2148868762 cites W1988750482 @default.
• W2148868762 cites W2024535319 @default.
• W2148868762 cites W2034440069 @default.
• W2148868762 cites W2043517681 @default.
• W2148868762 cites W2057559630 @default.
• W2148868762 cites W2060691994 @default.
• W2148868762 cites W2082509443 @default.
• W2148868762 cites W2090172660 @default.
• W2148868762 cites W2090721406 @default.
• W2148868762 cites W2117349291 @default.
• W2148868762 cites W2134798824 @default.
• W2148868762 cites W2150175350 @default.
• W2148868762 cites W2155601089 @default.
• W2148868762 cites W2167421884 @default.
• W2148868762 cites W2325910649 @default.
• W2148868762 cites W2481019689 @default.
• W2148868762 cites W2796129716 @default.
• W2148868762 doi "https://doi.org/10.1016/j.jvs.2008.03.029" @default.
• W2148868762 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18502082" @default.
• W2148868762 hasPublicationYear "2008" @default.
• W2148868762 type Work @default.
• W2148868762 sameAs 2148868762 @default.
• W2148868762 citedByCount "22" @default.
• W2148868762 countsByYear W21488687622012 @default.
• W2148868762 countsByYear W21488687622013 @default.
• W2148868762 countsByYear W21488687622014 @default.
• W2148868762 countsByYear W21488687622015 @default.
• W2148868762 countsByYear W21488687622019 @default.
• W2148868762 countsByYear W21488687622021 @default.
• W2148868762 crossrefType "journal-article" @default.
• W2148868762 hasAuthorship W2148868762A5001451471 @default.
• W2148868762 hasAuthorship W2148868762A5013152941 @default.
• W2148868762 hasAuthorship W2148868762A5016288477 @default.
• W2148868762 hasAuthorship W2148868762A5024073608 @default.
• W2148868762 hasAuthorship W2148868762A5058061659 @default.
• W2148868762 hasAuthorship W2148868762A5058704158 @default.
• W2148868762 hasBestOaLocation W21488687621 @default.
• W2148868762 hasConcept C126322002 @default.
• W2148868762 hasConcept C141071460 @default.
• W2148868762 hasConcept C188816634 @default.
• W2148868762 hasConcept C194828623 @default.
• W2148868762 hasConcept C2777010666 @default.
• W2148868762 hasConcept C2778789114 @default.
• W2148868762 hasConcept C2779159551 @default.
• W2148868762 hasConcept C71924100 @default.
• W2148868762 hasConcept C81182388 @default.
• W2148868762 hasConceptScore W2148868762C126322002 @default.
• W2148868762 hasConceptScore W2148868762C141071460 @default.
• W2148868762 hasConceptScore W2148868762C188816634 @default.
• W2148868762 hasConceptScore W2148868762C194828623 @default.
• W2148868762 hasConceptScore W2148868762C2777010666 @default.
• W2148868762 hasConceptScore W2148868762C2778789114 @default.
• W2148868762 hasConceptScore W2148868762C2779159551 @default.
• W2148868762 hasConceptScore W2148868762C71924100 @default.
• W2148868762 hasConceptScore W2148868762C81182388 @default.
• W2148868762 hasIssue "2" @default.
• W2148868762 hasLocation W21488687621 @default.
• W2148868762 hasLocation W21488687622 @default.
• W2148868762 hasOpenAccess W2148868762 @default.
• W2148868762 hasPrimaryLocation W21488687621 @default.
• W2148868762 hasRelatedWork W2047967234 @default.
• W2148868762 hasRelatedWork W2105290084 @default.
• W2148868762 hasRelatedWork W2409149935 @default.
• W2148868762 hasRelatedWork W2417961914 @default.
• W2148868762 hasRelatedWork W2439875401 @default.
• W2148868762 hasRelatedWork W2474039552 @default.
• W2148868762 hasRelatedWork W2901892643 @default.
• W2148868762 hasRelatedWork W2945124548 @default.
• W2148868762 hasRelatedWork W3179786606 @default.
• W2148868762 hasRelatedWork W62711790 @default.
• W2148868762 hasVolume "48" @default.
• W2148868762 isParatext "false" @default.
• W2148868762 isRetracted "false" @default.
• W2148868762 magId "2148868762" @default.
• W2148868762 workType "article" @default.